Guggenheim Assumes Neurocrine Bio. (NBIX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $144.21 +0.72%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 35
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 35
Join SI Premium – FREE
Guggenheim analyst Delma Caiati assumes coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target of $207.00.
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $143.18 yesterday.
You May Also Be Interested In
- Goldman Sachs Reinstates Hitachi Construction Machinery Co Ltd (6305:JP) (HTCMY) at Sell
- Canaccord Resumes D2L Inc. (DTOL:CN) at Buy
- Guggenheim Starts Ovid Therapeutics Inc (OVID) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
